Post-Procedure Skincare: What the Evidence Supports

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Timothy Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

Read this part first

This article describes what the published literature reports about topical products used after cosmetic procedures. It is not aftercare instructions.

If you have had laser resurfacing, microneedling, a chemical peel or any similar procedure, the person who performed it knows your skin, your settings, your depth of treatment and your complications risk. Their protocol takes precedence over anything written here and over anything printed on a product box. Post-procedure skin has a compromised barrier and a genuine risk of infection, prolonged erythema and post-inflammatory hyperpigmentation. This is the one area of skincare where improvising costs more than money.

With that established, the literature is genuinely interesting — mostly for what it fails to show.

The overall evidence grade is low, and the authors say so

The most directly relevant synthesis is a 2021 review in the Journal of Clinical and Aesthetic Dermatology by Angra and colleagues, examining topical agents used after laser resurfacing for improved healing and cosmesis Angra 2021.

Its central finding is a caveat about itself. The authors report that most studies in their review were found to have a level of evidence below Level 1, which prevented them from making strong recommendations for any single agent Angra 2021. In a field where products are sold at significant markup specifically for use on freshly wounded skin, that is the most important sentence in the literature.

It does not mean nothing works. It means that the confident hierarchy implied by the marketing does not exist in the evidence Angra 2021.

What performed best

Within that limitation, some agents did better than others.

Tripeptide and hexapeptide products showed the broadest benefits in the review, reducing adverse effects, assisting wound healing and improving cosmetic outcomes Angra 2021. Among the agents examined, these had the widest spread of positive findings.

Conjugated linolenic acid improved cosmetic outcomes with statistical significance Angra 2021.

Thermal spring water reduced pain, pruritus and erythema Angra 2021 — an unglamorous intervention that addresses the symptoms patients actually complain about in the first days.

Silicone-based gels reduced erythema and hyperpigmentation Angra 2021, consistent with their long established use in scar management.

The pattern is worth noticing. The agents with the most supportive findings are largely simple, inexpensive and mechanically straightforward: small peptides, a fatty acid, mineral water, an occlusive silicone. None of them require a novel biological mechanism to explain their effect.

What underperformed its marketing

Two findings in the same review deserve particular attention, because they concern the exact ingredient classes that the regenerative skincare category is built on.

Recombinant human epidermal growth factor produced subjective improvements but "no objective, statistically significant improvement" Angra 2021. Patients felt it was helping. The measurements did not agree. That gap between subjective and objective outcomes is exactly what an uncontrolled or unblinded study design tends to produce, and exactly why blinding matters.

Red deer umbilical cord lining extract — the cord-lining-derived conditioned media ingredient class that underpins much of the premium regenerative aftercare market — reduced post-procedure skin sensitivity but showed no significant differences in traditional healing metrics Angra 2021.

That is a fair and specific result, and it is worth stating precisely rather than dismissively. Reduced sensitivity is a real benefit; skin that stings less after a procedure is a better experience, and comfort is not nothing. But it is a different claim from accelerated healing or improved final cosmetic outcome, and it is the accelerated-healing claim that the category generally markets. When the same review measured the healing metrics directly, the difference did not reach significance Angra 2021.

Why this category attracts weak evidence

Post-procedure skincare has structural features that make good studies hard and marketing easy. The skin is healing anyway. Almost any reasonable product applied to a healing wound will be followed by improvement, because the improvement was going to happen. Without a control arm, the product takes credit for the biology. This is the same problem that limits the skin rejuvenation and hair literature covered elsewhere in this series: a 2026 systematic review of exosome skin therapies found most of its 19 human studies were not randomised and could not be pooled Flores Rodríguez 2026.

Patients are also highly motivated and have usually just paid a great deal for the procedure itself, which makes subjective outcome measures unreliable in exactly the direction the manufacturer would prefer. The recombinant EGF result — subjective improvement without objective change — is that effect made visible Angra 2021.

There is also a supply-side question. Health Canada's April 2026 final notice on topical products containing human-derived exosomes, extracellular vesicles and cell conditioned media flags unsubstantiated therapeutic claims, potential toxic effects, and the possibility of transmitting infectious diseases and adventitious agents from human-origin material Health Canada 2026. Applying biologically derived material to deliberately wounded skin is precisely the scenario where sourcing and characterisation matter most, and where the absence of standardisation reported in the cosmetics literature Villarreal-Gómez 2025 is least comfortable.

The practical reading

The honest summary of this literature is that post-procedure skincare is mostly about not doing harm. The barrier is compromised, it will repair itself, and the job of a topical product is to avoid interfering while that happens. The agents with the best evidence are the ones that do simple things: occlude, soothe, and stay out of the way.

Expensive regenerative aftercare products are not fraudulent, and at least one ingredient class has a documented benefit in reduced sensitivity Angra 2021. But the evidence does not currently support paying a premium for faster or better healing, because the studies that measured healing directly did not find that difference Angra 2021.

And the instruction that carries the most weight is still the free one: do what the clinician who performed your procedure tells you to do, and call them rather than a product website if something looks wrong.

References